Compare MKSI & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKSI | ILMN |
|---|---|---|
| Founded | 1961 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9B | 24.6B |
| IPO Year | 1997 | 2000 |
| Metric | MKSI | ILMN |
|---|---|---|
| Price | $344.73 | $164.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 17 |
| Target Price | ★ $263.31 | $124.24 |
| AVG Volume (30 Days) | 975.9K | ★ 1.8M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | 55.52 | ★ 170.87 |
| EPS | ★ 1.18 | 0.87 |
| Revenue | $3,931,000,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $15.87 | $6.47 |
| Revenue Next Year | $10.87 | $5.58 |
| P/E Ratio | $292.65 | ★ $190.79 |
| Revenue Growth | ★ 9.62 | N/A |
| 52 Week Low | $88.49 | $86.03 |
| 52 Week High | $347.27 | $177.22 |
| Indicator | MKSI | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 63.43 | 65.25 |
| Support Level | $131.70 | $116.54 |
| Resistance Level | N/A | $177.22 |
| Average True Range (ATR) | 16.26 | 6.70 |
| MACD | -0.85 | -0.08 |
| Stochastic Oscillator | 98.50 | 63.80 |
MKS Inc delivers foundational technology solutions for leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. The company provides instruments, components, subsystems, systems, process control solutions, and specialty chemicals technology that improve process performance and optimize productivity. Its solutions address challenges of miniaturization and complexity in device manufacturing, enabling increased power, speed, and feature enhancement. MKS Inc operates through three divisions: Vacuum Solutions Division (VSD), Photonics Solutions Division (PSD), and Materials Solutions Division (MSD). The company operates in the United States, which generates maximum revenue, as well as China and other countries.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.